- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06206460
Follow-up Assessment of a Trial of Open-label Placebos for Women With Premenstrual Syndrome
Follow-up Assessment of the Randomized Controlled Trial: Open-label Placebo Treatment of Women With Premenstrual Syndrome: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Antje F Nascimento, PhD
- Phone Number: (+41) 061 207 02 12
- Email: antje.freynascimento@unibas.ch
Study Locations
-
-
-
Basel, Switzerland, 4055
- Recruiting
- University of Basel, Faculty of Psychology, Division of Clinical Psychology and Psychotherapy
-
Contact:
- Antje F Nascimento, PhD
- Phone Number: (+41) 061 207 02 12
- Email: antje.freynascimento@unibas.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants are willing to participate in the follow-up study
- Participants have the ability to use an electronic device with internet access to complete the online follow-up survey
- Participants give Informed consent
- Participants have a regular menstruation (i.e., no menopause; pregnancy; cycle inhibiting medication etc.)
Exclusion Criteria:
- Pregnancy or breastfeeding (currently or within the last three months)
- A severe psychological or somatic disease, affecting premenstrual complaints (e.g., cancer of the uterus or fallopian tubes)
- Commencement of the menopause, sterilization, or (part) resection of the uterus or fallopian tubes
- Changes in body mass index (i.e., under 18 or above 30)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Open Label Placebo with Treatment Rationale
|
Online Assessment which consists of:
|
Open Label Placebo without Treatment Rationale
|
Online Assessment which consists of:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom intensity of premenstrual syndrome
Time Frame: One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
The items of the German PMS [Premenstrual Syndrome] Symptom diary will be used to measure symptom intensity retrospectively for the last luteal phase ( i.e., PMS phase).
The scale consists of 27 items measured on a 6-point Likert scale.
A decrease in scores indicates an improvement in symptom intensity.
The minimum score is zero; the maximum 162.
|
One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Interference of premenstrual syndrome
Time Frame: One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
The items of the German PMS [Premenstrual Syndrome] Symptom diary will be used to measure interference retrospectively for the last luteal phase ( i.e., PMS phase). The scale consists of 3 items measured on a 6-point Likert scale. A decrease in scores indicates an improvement in interference. The minimum score is zero; the maximum 162. |
One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (Short-Form-12)
Time Frame: One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Quality of life will be measured by means of the SF-12 (Short-Form-12) questionnaire retrospectively for the last luteal phase (i.e., PMS phase).
The questionnaire comprises 12 questions, and quality of life is measured on a 6-point Likert scale.
Two summary scores can be calculated: a mental component and a physical component score.
Scores range from 0-100, with higher scores indicating better functioning.
|
One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Partnership satisfaction (Zufriedenheit in der Partnerschaft: ZIP)
Time Frame: One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Partnership satisfaction will be measured by means of the ZIP (Zufriedenheit in der Partnerschaft) questionnaire retrospectively for the last luteal phase (i.e., PMS phase).
The questionnaire comprises 7 questions, and partnership satisfaction is measured on a 5-point rating scale.
Scores range from 7 to 35.
|
One time assessment at baseline (the start day 1-3 of the next menstrual cycle retrospectively for the last luteal phase)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-02187; ub24Frey
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premenstrual Syndrome
-
Esra ÖZERKTO Karatay UniversityRecruitingPremenstrual Syndrome-PMSTurkey
-
Shaare Zedek Medical CenterUnknownPremenstrual Syndrome-PMS
-
Philipps University Marburg Medical CenterLinkoeping UniversityCompletedPremenstrual Syndrome (PMS)Germany
-
Cairo UniversityNot yet recruitingPremenstrual Tension
-
Cairo UniversityNot yet recruitingPremenstrual Pain
-
Terra Biological LLCCompletedPremenstrual Syndrome (PMS)
-
Massachusetts General HospitalWithdrawnPremenstrual Dysphoric Disorder | Premenstrual Syndrome | Premenstrual Tension | Menstrual Related Mood DisorderUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownDepression | Premenstrual Dysphoric Disorder (PMDD)Israel
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedPremenstrual SyndromeUnited States
Clinical Trials on Online Assessment
-
Cedars-Sinai Medical CenterHarvard Medical School (HMS and HSDM); National Institute of Diabetes and Digestive... and other collaboratorsWithdrawn
-
Kaiser PermanentePatient-Centered Outcomes Research InstituteActive, not recruitingBreast Cancer | Colorectal Cancer | Ovarian Cancer | Lynch Syndrome | Genetic Predisposition | Family CharacteristicsUnited States
-
Prof. Evelien Dekker, MD, PhDDutch Digestive Diseases FoundationCompletedColorectal Cancer | Lynch Syndrome | Familial Colorectal Cancer
-
University Health Network, TorontoRecruiting
-
National Institute of Occupational Health, NorwayNorwegian Labour Inspection AuthorityCompletedOccupational Exposure | Occupational Health | Sick LeaveNorway
-
Centre Hospitalier Universitaire de BesanconSaint Anne's HospitalUnknown
-
University of RochesterCharles River AnalyticsCompletedCancer-Related Cognitive Difficulties | Cancer-Related Cognitive ImpairmentUnited States
-
Hannah Palma CarlosCompletedPostpartum DepressionUnited Kingdom
-
The Netherlands Cancer InstituteRadboud University Medical Center; Erasmus Medical Center; Dutch Cancer SocietyUnknownCardiovascular Diseases | Quality of Life | Cognitive Decline | BRCA1 Mutation | BRCA2 Mutation | Bone Mineral Density | Surgical Menopause | Menopause SurgicalNetherlands
-
Yale-NUS CollegeCompleted